ID 111576
Title Alternative
A study on 80 patients with type 2 diabetes who were administered SGLT2 inhibitor at our clinic. : SGLT2 inhibitor is the strongest drug for treating diabetic nephropathy
Author
Inomoto, Takashi Inomoto Clinic Ophthalmology and Internal medicine
Keywords
SGLT2 inhibitor
diabetic nephropathy
albuminuria
patient satisfaction
hepatoprotective effect
Content Type
Journal Article
Description
We analyzed 80 patients with type 2 diabetes who were administered SGLT2 inhibitor at our clinic. Side effects such as muscle weakness, vaginal candidiasis and urinary ketone-positive were observed, but there were no hypoglycemia cases that needed the drug reduction. There were only 2 cases of discontinuation of treatment and the reason for high patient satisfaction seemed to be due to weight loss being likely to occur. Combined use of SGLT2 inhibitor in obese patients being treated with SU drug and insulin preparation resulted in a decrease in body weight and HbA1c value and dose reduction of SU drug and insulin preparation were possible. After administration, body weight, systolic blood pressure, diastolic blood pressure, HbA1c, uric acid and GPT levels decreased significantly. As I already reported, when SGLT2 inhibitor was administered to 29 patients with diabetic nephropathy, albuminuria decreased about 50% after 6 months, about 70% after1year and about 80% after 1.5 years and these reduction rates were much higher than those of RAS inhibitors which efficacy against diabetic nephropathy has already been established, and SGLT2 inhibitors have been reported to be the strongest drug for treating diabetic nephropathy and the decrease in eGFR value has been reported to be due to a decrease in glomerular internal pressure. Analysis in 80 cases of this time also showed a decrease in eGFR value during the administration period, and it seems that the reduction of eGFR value works to maintain the renal function in the long term.
Journal Title
Shikoku Acta Medica
ISSN
00373699
NCID
AN00102041
Publisher
徳島医学会
Volume
74
Issue
1-2
Start Page
47
End Page
54
Sort Key
47
Published Date
2018-04-25
FullText File
language
jpn
TextVersion
Publisher